215
edits
Changes
Jump to navigation
Jump to search
*Outcome Measures ==Example XML==
*URL <clinical_study rank="91460"> <!-- This xml conforms to an XML Schema at: https://clinicaltrials.gov/ct2/html/images/info/public.xsd --> <required_header> <download_date> ClinicalTrials.gov processed this data on January 11, 2017 </download_date> <link_text>Link to the current ClinicalTrials.gov record.</link_text> <url>https://clinicaltrials.gov/show/NCT00002322</url> </required_header> <id_info> <org_study_id>210A</org_study_id> <secondary_id>M/3330/0018</secondary_id> <nct_id>NCT00002322</nct_id> </id_info> <brief_title> A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients </brief_title> <official_title> Randomized, Double-Blind, Placebo-Controlled Comparative Dose-Response Study of Two Doses of Atevirdine Mesylate (U-87201E) in Combination With Fixed Doses of Zidovudine (AZT) in HIV+ Patients </official_title> <sponsors> <lead_sponsor> <agency>Pharmacia and Upjohn</agency> <agency_class>Industry</agency_class> </lead_sponsor> </sponsors> <source>NIH AIDS Clinical Trials Information Service</source> <oversight_info> <authority>United States: Food and Drug Administration</authority> </oversight_info> <brief_summary> <textblock> To determine the tolerance and antiviral response of two different doses of atevirdine mesylate (U-87201E) in symptomatic HIV-positive patients with CD4 counts of 50-350 cells/mm3, who also take zidovudine (AZT). </textblock> </brief_summary> <detailed_description> <textblock> Patients are randomized to 1 of 3 treatment groups: U-87201E at 1 of 2 doses or placebo administered every 8 hours. Patients must have taken AZT for at least 3 months prior to randomization. </textblock> </detailed_description> <overall_status>Completed</overall_status> <phase>Phase 2</phase> <study_type>Interventional</study_type> <study_design> Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment </study_design> <condition>HIV Infections</condition> <intervention> <intervention_type>Drug</intervention_type> <intervention_name>Atevirdine mesylate</intervention_name> </intervention> <intervention>...</intervention> <eligibility> <criteria> <textblock> Inclusion Criteria Concurrent Medication: Allowed: - Primary or secondary prophylaxis for opportunistic infections. Patients must have: - HIV infection. - Symptoms (currently or prior to enrollment) included in Category B or C of CDC classification, although THE FOLLOWING CURRENT ACUTE MEDICAL CONDITIONS ARE NOT ALLOWED: - Cryptococcosis - Pneumocystis carinii pneumonia - Herpes zoster - Histoplasmosis - CMV - Hepatic or renal disease - Lymphoma. - CD4 count 50 - 350 cells/mm3 within 14 days prior to study entry. - Ongoing therapy with AZT at 500 - 600 mg total daily dose for at least 3 months prior to study entry. - Consent of parent, guardian, or person with power of attorney if less than 18 years of age. Exclusion Criteria Co-existing Condition: Patients with the following conditions are excluded: - Intolerance to AZT. - Current diagnosis of malignancy for which systemic therapy will be required during the study. Concurrent Medication: Excluded: - Any other investigational drugs. Prior Medication: Excluded: - Cytotoxic chemotherapy within 1 month prior to study entry. - Prior U-87201E or any other non-nucleoside antiretroviral medications, including but not limited to nevirapine, TIBO R-82150 or TIBO R-82913, L-697639 or L-696229, U-90152S, or any protease inhibitors. - Antiretroviral agents other than AZT within 3 months prior to study entry. Required: - AZT for at least 3 months prior to study entry. Present use of excessive alcohol or illicit drugs. </textblock> </criteria> <gender>Both</gender> <minimum_age>13 Years</minimum_age> <maximum_age>N/A</maximum_age> <healthy_volunteers>No</healthy_volunteers> </eligibility> <location> <facility> <name> Los Angeles County / Health Research Assoc / Drew Med Ctr </name> <address> <city>Los Angeles</city> <state>California</state> <zip>90033</zip> <country>United States</country> </address> </facility> </location> <location>...</location> ... <location_countries>...</location_countries> <verification_date>November 1996</verification_date> <lastchanged_date>June 23, 2005</lastchanged_date> <firstreceived_date>November 2, 1999</firstreceived_date> <keyword>Drug Therapy, Combination</keyword> <keyword>Acquired Immunodeficiency Syndrome</keyword> <keyword>AIDS-Related Complex</keyword> <keyword>Antiviral Agents</keyword> <has_expanded_access>No</has_expanded_access> <condition_browse> <!-- CAUTION: The following MeSH terms are assigned with an imperfect algorithm --> <mesh_term>HIV Infections</mesh_term> </condition_browse> <intervention_browse> <!-- CAUTION: The following MeSH terms are assigned with an imperfect algorithm --> <mesh_term>Zidovudine</mesh_term> <mesh_term>Atevirdine</mesh_term> </intervention_browse> <!-- Results have not yet been posted for this study --> </clinical_study>
no edit summary
'''Contains:'''
*Rank
*NCT Number
*Title
*Recruitment
*Study Results
*Conditions
*Interventions
*Sponsor/Collaborators
*Gender
*Age
*Phases
*Enrollment
*Funded Bys
*Study Types
*Study Designs
*Other IDs
*First Received
*Start Date
*Completion Date
*Last Updated
*Last Verified
*Results First Received
*Acronym
*Primary Completion Date
*Outcome Measures
*URL
